DeCure for Non-acquired combined pituitary hormone deficiency with spine abnormalities
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for non-acquired combined pituitary hormone deficiency with spine abnormalities — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNon-acquired combined pituitary hormone deficiency with spine abnormalities maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for non-acquired combined pituitary hormone deficiency with spine abnormalities is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The four abstracts provided are review articles and a two-patient case report; none describe a clinical trial of any drug for non-acquired combined pituitary hormone deficiency with spine abnormalities. The 2003 case report of two brothers with a PROP-1 gene mutation followed for 40 years found that despite long-standing untreated hypopituitarism, both had normal physical and professional activity. Bone mineral density was low in only one patient, and adrenocortical deficiency appeared late, at ages 45 and 39. The authors concluded that hormonal deficiencies do not necessarily lead to the same phenotype, as shown by differences in bone age and bone mineral density between the two brothers.
The 2011 review of novel mutations in combined pituitary hormone deficiency states that the condition may present in infants or children with unknown cause, and that clinical presentation can be dynamic, with new hormone deficiencies developing over time. It notes that characterising patients with mutations in pituitary development genes may reveal novel mechanisms, and that genetic screening could offer diagnostic and therapeutic insights. The 2011 chapter on molecular genetics of congenital growth hormone deficiency reports that the incidence of identified mutations in patients with growth hormone deficiency remains low, and that there is a wide spectrum of clinical presentations, making genotype-phenotype correlations difficult.
The 2024 update on hypopituitarism states that pituitary neuroendocrine tumours cause about half of adult cases, while childhood causes are predominantly congenital. It says hormone replacement therapy is the mainstay of treatment and significantly improves quality of life, but does not name any specific drug or report any trial results. The 1997 review lists causes and effects of hypopituitarism but offers no treatment data. No abstract mentions a drug being tested or repurposed for this disease. What is missing is any clinical trial evidence, any drug candidate, any patient stratification beyond the two brothers, and any funding for a trial designed to test a specific intervention in this rare condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Molecular Endocrinology · 2011 · 40 citations · open access
Novel mutations associated with combined pituitary hormone deficiency
AbstractThe pituitary gland produces hormones that play important roles in both the development and the homeostasis of the body. A deficiency of two or several of these pituitary hormones, known as combined pituitary hormone deficiency, may present in infants or children due to an unknown etiology and is considered congenital or idiopathic. Advancements in our understanding of pituitary development have provided a genetic basis to explain the pathophysiological basis of pituitary hormone disease. Nevertheless, there are several challenges to the precise characterization of abnormal genotypes; these exist secondary to the complexities of several of the hypothalamic/pituitary developmental factors and signals, which ultimately integrate in a temporal and spatial dependent manner to produce a mature gland. Furthermore, the clinical presentation of pituitary hormone disease may be dynamic as subsequent hormone deficiencies may develop over time. The characterization of patients with mutations in genes responsible for pituitary development provides an opportunity to discover potential novel mechanisms responsible for pituitary pathophysiology. The focus of this review is to report the most recent mutations in genes responsible for pituitary development in patients with hypopituitarism and emphasize the importance to physicians and researchers for characterizing these patients. Continuing efforts toward understanding the molecular basis of pituitary development as well as genetic screening of patients with pituitary disease will offer new insights into both diagnostic and potential therapeutic options that will decrease the morbidity and mortality in patients with hypopituitarism.
Journal of Clinical Medicine · 2024 · 29 citations · open access
An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management
AbstractThis article provides an updated review of hypopituitarism (HP), an endocrine disorder characterized by a deficiency of one or more pituitary hormones. The various etiologies are reviewed, including pituitary neuroendocrine tumors (PitNETs), hypothalamic lesions, genetic mutations, and acquired factors such as head trauma, medications, neoplasms, and infiltrative diseases. It is noted that PitNETs are responsible for approximately half of the cases in adults, whereas in children the causes are predominantly congenital. Diagnosis is based on clinical evaluation and hormonal testing, with identification of the specific hormonal deficiencies essential for effective treatment. Laboratory tests present challenges and limitations that must be understood and addressed. Hormone replacement therapy is the mainstay of treatment, significantly improving patients' quality of life. It is important to know the possible interactions between hormone replacement therapies in HP. Recent advances in understanding the pathophysiology of HP and the importance of a multidisciplinary approach to the management of associated complications are discussed. This article emphasizes the need for comprehensive evaluation and continuous follow-up to optimize outcomes in patients with HP and highlights the importance of ongoing research to improve diagnostic and treatment strategies.
Hormone Research in Paediatrics · 2003 · 25 citations
Long-Term Follow-Up of Childhood-Onset Hypopituitarism in Patients with the PROP-1 Gene Mutation
AbstractOBJECTIVE: The PROP-1 gene mutation is a rare disorder leading to combined pituitary hormone deficiencies over time. The aim was to analyze the clinical picture of 40 years of an almost untreated PROP-1 gene mutation. METHODS: We describe the clinical and hormonal data of 2 brothers from childhood to adulthood as well as imaging procedures (MRI of the pituitary gland, bone mineral density by QCT and DPX). The PROP-1 gene mutation (301-302delAG) was confirmed by DNA sequencing. RESULTS: Although long-standing untreated hypopituitarism was present, there was normal physical and professional activity. Bone mineral density was low only in 1 patient. Adrenocortical deficiency occurred late at 45 and 39 years. CONCLUSIONS: The biological evolution of the PROP-1 gene mutation illustrates the importance of continuous care for these patients. Hormonal deficiencies do not necessarily lead to the same phenotype as is obvious in differences of bone age and bone mineral density.
AbstractHypopituitarism refers to the congenital absence or acquired loss of pituitary hormone secretion, which may be an isolated deficiency or multiple hormone deficiencies. The diagnosis of pituitary hormone deficiency can usually be made in the outpatient setting with a combination of the clinical assessment and hormone measurements. Hypopituitarism is most commonly acquired, and occurs most often with pituitary disease, usually a benign adenoma. Pituitary failure may also result from treatment of the adenoma (surgery, radiation). Causes of pituitary hormone deficiency are listed in Table 1 (1–23). The loss of pituitary function has numerous effects, depending on which hormone or hormones is/are deficient. Table 2 lists the hypothalamic and pituitary hormones and target organs. It is apparent from this list that some deficiencies can be life threatening, i.e., adrenocorticotropin (ACTH) deficiency results in adrenal insufficiency, thyrotropin (TSH) deficiency results in hypothyroidism. Loss of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) produce hypogonadism and infertility. If the posterior pituitary is compromised, diabetes insipidus (DI) results in polyuria and polydipsia; if the patient does not ingest adequate fluid, the resultant volume depletion and hypernatremia can be severe.KeywordsLuteinizing HormonePituitary AdenomaDiabetes InsipidusAdrenal InsufficiencyThyrotropin Release HormoneThese keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Molecular Genetics of Congenital Growth Hormone Deficiency
AbstractGrowth hormone deficiency (GHD) in patients is diagnosed as an isolated finding or in combination with other pituitary hormone deficiencies and classified as combined pituitary hormone deficiency (CPHD). Although any type of neurological insult such as trauma, radiation, or surgery place the pituitary at risk for injury and potential destruction of somatotrophs, a subgroup of patients develop idiopathic GHD who do not have a clear etiology. Advancements in understanding cellular and organ development as well as the availability of sophisticated genetic techniques have provided a molecular basis for some cases of idiopathic GHD. Genetic screening for mutations in pituitary development factors has resulted in the identification of a series of abnormalities in patients with GHD, resulting in hormone deficiency. Unfortunately, the incidence of identified mutations in this group remains low, and quite often, there is a wide spectrum of clinical presentations, which makes correlations between genotypes and abnormal phenotypes difficult. Nevertheless, the characterization of patients with GHD and the ongoing research efforts to decipher the complexities of pituitary development provide insight into the molecular basis of hypopituitarism. This chapter reviews the genetic defects that have been characterized in the hypothalamic-pituitary axis resulting in a deficiency of GH. Furthermore, it emphasizes the importance of continuing research efforts, which will offer physicians the means of determining a genetic etiology for patients with GHD and researchers the tools to develop definitive therapeutic options.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
